Bogdan Nicolae Manolescu1, Delia Cinteza2, Mihai Berteanu2, Carmina Busu3, Eliza Oprea4. 1. "C.D. Nenitescu" Department of Organic Chemistry, Faculty of Applied Chemistry and Science of Materials, Polytechnic University of Bucharest, Bucharest, Romania. 2. Department of Rehabilitation and Physical Medicine, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 3. Department of Functional Sciences, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 4. Department of Organic Chemistry, Biochemistry and Catalysis, Faculty of Chemistry, University of Bucharest, Romania.
Abstract
OBJECTIVES: Stroke is a pathological condition associated with a redox imbalance. Both the acute and the post-acute phases after a stroke are characterized by a pro-oxidant state, which could be corrected through antioxidant supplementation. The aim of the present study was to evaluate the effect of the ALAnerv(®) upon the redox status of erythrocytes. MATERIAL AND METHODS: For this pilot study were enrolled 28 post-acute stroke patients. They were randomly divided into a control group [(-) ALA] and a study group [(+) ALA]. Patients were hospitalized for a period of two weeks. Blood samples were taken at the beginning and at the end of this period. Patients from (+) ALA group received the nutritional supplement ALAnerv(®). Catalase, SOD, GPx, GRed and GT activities were assessed on erythrocytes' lysates. Also, the total antioxidant capacity as well as the concentration of total thiols were evaluated. OUTCOMES: During the study period only SOD (1393.48 ± 69.14 U/g Hb vs. 1514.06 ± 60.80) and GRed (4.47 ± 0.37 U/g Hb vs. 5.06 ± 0.24) significantly increased in (+) ALA group. Catalase (173.70 ± 14.62 k/g Hb vs. 123.41 ± 8.71) and GT (5.55 ± 0.26 U/g Hb vs. 4.95 ± 0.23) activities significantly decreased during the study period. Multiple regression indicated that only SOD, GT and GRed activities were influenced by the ALAnerv(®) consumption. There was no significant increase if the total thiols concentration. CONCLUSIONS:ALAnerv(®) consumption could be associated with a correction of the erythrocytes' redox status. There is a need to investigate if administration of ALAnerv(®) over a longer time period could have a more significant influence on the erythrocytes' antioxidant system.
RCT Entities:
OBJECTIVES:Stroke is a pathological condition associated with a redox imbalance. Both the acute and the post-acute phases after a stroke are characterized by a pro-oxidant state, which could be corrected through antioxidant supplementation. The aim of the present study was to evaluate the effect of the ALAnerv(®) upon the redox status of erythrocytes. MATERIAL AND METHODS: For this pilot study were enrolled 28 post-acute strokepatients. They were randomly divided into a control group [(-) ALA] and a study group [(+) ALA]. Patients were hospitalized for a period of two weeks. Blood samples were taken at the beginning and at the end of this period. Patients from (+) ALA group received the nutritional supplement ALAnerv(®). Catalase, SOD, GPx, GRed and GT activities were assessed on erythrocytes' lysates. Also, the total antioxidant capacity as well as the concentration of total thiols were evaluated. OUTCOMES: During the study period only SOD (1393.48 ± 69.14 U/g Hb vs. 1514.06 ± 60.80) and GRed (4.47 ± 0.37 U/g Hb vs. 5.06 ± 0.24) significantly increased in (+) ALA group. Catalase (173.70 ± 14.62 k/g Hb vs. 123.41 ± 8.71) and GT (5.55 ± 0.26 U/g Hb vs. 4.95 ± 0.23) activities significantly decreased during the study period. Multiple regression indicated that only SOD, GT and GRed activities were influenced by the ALAnerv(®) consumption. There was no significant increase if the total thiols concentration. CONCLUSIONS:ALAnerv(®) consumption could be associated with a correction of the erythrocytes' redox status. There is a need to investigate if administration of ALAnerv(®) over a longer time period could have a more significant influence on the erythrocytes' antioxidant system.
Authors: D Han; G Handelman; L Marcocci; C K Sen; S Roy; H Kobuchi; H J Tritschler; L Flohé; L Packer Journal: Biofactors Date: 1997 Impact factor: 6.113
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245